A clinical perspective on COVID-19, ACE2 and RAAS inhibition

Lecture 2 out of 3

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD - University of Miami, FL, USA

Video navigation menu

How the controversy on RAASi use during COVID-19 pandemic started 01:00
Overriding risks of withdrawal of ACEi/ARBs in COVID-19 patients 03:39
Potential therapeutic options in COVID-19 07:54
Take home messages 15:14
An add-on on sustained treatment with RAASi while obviating hyperkalemia 16:31

Educational information

The educational objective of this series of 3 videos is to provide cardiovascular physicians with current insights in ACE2 and the use of RAASi in the management of patients with COVID-19.

Faculty

Murray Epstein, M.D., is emeritus professor of medicine at the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine, Miami, FL, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

This educational program was sponsored by unrestricted educational grants from Vifor Pharma and Novartis.

Watch a scientifc perspective on this topic Watch a discussion between experts on this topic

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.